Welcome to our dedicated page for Edap Tms news (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on Edap Tms stock.
EDAP TMS SA (NASDAQ: EDAP) delivers innovative therapeutic ultrasound solutions for urological care through its HIFU and lithotripsy technologies. This news hub provides investors and medical professionals with essential updates on the company's advancements in robotic medical devices, regulatory milestones, and global market strategies.
Access real-time announcements including clinical trial results, product approvals, financial disclosures, and strategic partnerships. Our curated collection features press releases about EDAP's three operational divisions: HIFU tumor ablation systems, ESWL stone treatment devices, and distribution of complementary medical technologies.
Stay informed about developments in minimally-invasive treatment solutions that demonstrate EDAP's commitment to advancing urological care. The resource is regularly updated with material events affecting the company's position in the competitive medical devices sector.
Bookmark this page for streamlined access to verified information about EDAP's technological innovations, international expansion efforts, and research collaborations with leading medical institutions.
EDAP TMS SA (Nasdaq: EDAP) highlighted its Focal One Robotic HIFU treatment for prostate cancer through a national television feature on Health Uncensored with Dr. Drew on the Lifetime Network. The segment, aired on September 26, 2025, featured patient Peter D. from Austin, TX, sharing his successful treatment experience.
The broadcast was part of EDAP's Prostate Cancer Awareness Month campaign, which included multiple patient education events and hospital partnerships. Dr. Eric Giesler from Urology Austin emphasized how Focal One provides a non-invasive treatment option that precisely targets prostate cancer while minimizing side effects compared to traditional radical treatments like surgery and radiotherapy.
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has received the prestigious 2025 Industry Award for Innovations in Endourological Instrumentation from the Endourological Society for its Focal One High-Intensity Focused Ultrasound (HIFU) platform.
The award, presented at the 42nd World Congress of Endourology and Uro-Technology, recognizes Focal One as the first Focal Therapy technology to receive this distinction. The platform was honored for its pioneering development in robotic HIFU for prostate cancer treatment.
EDAP TMS SA (Nasdaq: EDAP) has achieved a significant milestone with the French Ministry of Health granting reimbursement coverage for its Focal One Robotic HIFU (High Intensity Focused Ultrasound) procedure for prostate cancer treatment in France. The coverage, effective September 1, 2025, includes both primary treatment of localized prostate cancer and salvage treatment following radiotherapy under France's national universal health system.
The reimbursement approval was supported by positive results from the HIFI Study and additional evidence from the FARP Study. CEO Ryan Rhodes highlighted that this achievement could accelerate similar reimbursement approvals across other European countries and drive further adoption of the Focal One platform.
EDAP TMS SA (NASDAQ: EDAP) reported strong Q2 2025 results, highlighted by exceptional growth in its core HIFU business. The company achieved 76.8% year-over-year HIFU revenue growth to EUR 8.5 million, driven by nine Focal One system sales versus three in Q2 2024. Total revenue reached EUR 16.0 million, up 1.6% year-over-year.
Key developments include a 36 million Euro credit facility letter of intent with the European Investment Bank and increased 2025 HIFU revenue growth guidance to 26-34% from previous 16-25%. The company reported a Q2 2025 net loss of EUR 5.6 million (EUR 0.15 per share), improved from EUR 6.1 million loss in Q2 2024.
EDAP's strategic focus on its high-margin HIFU business resulted in improved gross margins of 42.5% in Q2 2025, up from 37.5% in Q2 2024, while the company continues planned reduction of non-core ESWL and Distribution operations.
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has secured a letter of intent for a €36 million credit facility from the European Investment Bank (EIB). The financing will support the expansion of Focal One® Robotic HIFU technology for early-stage prostate cancer treatment and accelerate development of new clinical indications.
The credit facility, expected to close by the end of 2025, will provide low-interest funding accessible in tranches. CEO Ryan Rhodes highlighted that this strategic financing will strengthen EDAP's balance sheet and help expand access to Focal One Robotic HIFU technology for physicians and patients.
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Ryan Rhodes will engage in a fireside chat and conduct one-on-one investor meetings during the event.
The presentation is scheduled for Tuesday, September 9th, 2025, from 8:30-9:00 AM ET at the Lotte New York Palace Hotel. Investors can access both the live and archived webcast through the company's investor relations website.
EDAP TMS (NASDAQ:EDAP), the global leader in robotic energy-based therapies, will release its Q2 2025 financial results on Thursday, August 28th, 2025, before market open.
The company will host a conference call and webcast at 8:30 AM EDT on the same day, featuring CEO Ryan Rhodes, CFO Ken Mobeck, and CAO François Dietsch. Investors can access the call via domestic (1-800-274-8461) or international (1-203-518-9814) numbers using passcode EDAP, or through the company's webcast platform.
EDAP TMS (NASDAQ:EDAP), the global leader in robotic energy-based therapies, announced its transition from foreign private issuer status to U.S. domestic filer status, effective January 1, 2026.
The transition will require EDAP to comply with SEC reporting rules and Nasdaq listing requirements applicable to U.S. domestic filers, including new requirements regarding board composition, corporate governance matters, and shareholder approval processes. CEO Ryan Rhodes emphasized this change as a significant milestone that demonstrates the company's commitment to transparency and regulatory best practices.
EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Ryan Rhodes will deliver a presentation and conduct one-on-one investor meetings during the conference, scheduled for June 3-5, 2025, in New York City.
Rhodes' presentation is set for Thursday, June 5th, from 4:20-4:50 PM ET. Investors can access both the live and archived webcast of the presentation through the company's website's Investor section or via the provided webcast link.
FAQ
What is the current stock price of Edap Tms (EDAP)?
What is the market cap of Edap Tms (EDAP)?
